PF-5230895 / Emergent Biosolutions, Pfizer - LARVOL DELTA

Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. (PubMed, Ann Rheum Dis) - "This SLR informed the task force regarding the evidence base of various therapeutic regimen for the development of the update of EULAR's RA management recommendation."

Clinical • Journal • Immunology • Rheumatoid Arthritis • Rheumatology

J.P. Morgan Healthcare Conference (Emergent Biosolutions) - Pfizer completed enrollment for SBI-087 P2 dose finding study in RA & completed dosing for P1 safety & PK study in SLE; Anticipated data from P2 dose regimen finding study in RA by Pfizer in H1 '12

Anticipated P2 trial data • Enrollment completion

Safety and efficacy of SBI-087 in subjects with active rheumatoid arthritis in a phase 2 randomized, double-blind, placebo-controlled study (EULAR 2012) - Presentation time: 07.06.2012; 10:50AM; Anticipated presentation at EULAR 2012

Anticipated P2 data • Immunology • Rheumatoid Arthritis

Safety and efficacy of SBI-087 in subjects with active rheumatoid arthritis in a phase 2 randomized, double-blind, placebo-controlled study (EULAR 2012) - P2, N=209; The 200 mg SBI-087 Day 1, 15, and Week 12 treatment arm achieved significant improvement in RA disease activity by week 16 compared to placebo

P2 data • Rheumatoid Arthritis

Study evaluating single doses of SBI-087 in subjects with rheumatoid arthritis (clinicaltrials.gov) - P1, N=62; Recruiting -> Completed; Completion date: Jun 2011 -> Mar 2011

Completion date • Trial completion • Immunology • Rheumatoid Arthritis